Building on the past to define an efficient path to an HIV vaccine

References

• Gilbert PB, Peterson ML, Follmann D et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a Phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis.191(5), 666–677 (2005).
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis.194(12), 1661–1671 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen J. Is an effective HIV vaccine feasible? Science309(5731), 99 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen J. HIV/AIDS. Hedged bet: an unusual AIDS vaccine trial. Science309(5737), 1003 (2005).
   Google Scholar
• Cohen J. AIDS research. Did Merck’s failed HIV vaccine cause harm? Science318(5853), 1048–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Promising AIDS vaccine’s failure leaves field reeling. Science318(5847), 28–29 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen J. HIV/AIDS research. Surprising AIDS vaccine success praised and pondered. Science326(5949), 26–27 (2009).
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet372(9653), 1894–1905 (2008).
   PubMed Web of Science ®Google Scholar
• Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on HIV vaccines. AIDS23(1), 3–8 (2009).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med.61, 153–167 (2010).
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for Phase III HIV-1 vaccine trials. Science303(5656), 316 (2004).
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Berger JO, Stablein D et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis.203(7), 969–975 (2011).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert P, Wang M, Wrin T et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis.202(4), 595–605 (2010).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Tehrani DM et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol.84(3), 1302–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6(2), 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Barnett SW, Burke B, Sun Y et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol.84(12), 5975–5985 (2010).
   PubMed Web of Science ®Google Scholar
• Pal R, Kalyanaraman VS, Nair BC et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology348(2), 341–353 (2006).
   PubMed Web of Science ®Google Scholar
• Korber B, Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS4(5), 408–417 (2009).
   PubMed Web of Science ®Google Scholar
• Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol.22(3), 358–366 (2010).
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Ackers ML, Berman PW et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J. Infect. Dis.192(6), 974–983 (2005).
   PubMed Web of Science ®Google Scholar
• Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol.178(10), 6596–6603 (2007).
   PubMed Web of Science ®Google Scholar
• Letvin NL, Mascola JR, Sun Y et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science312(5779), 1530–1533 (2006).
   PubMed Web of Science ®Google Scholar
• Liu J, O’Brien KL, Lynch DM et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature457(7225), 87–91 (2009).
   PubMed Web of Science ®Google Scholar
• Barouch DH, O’Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med.16(3), 319–323 (2010).
   PubMed Web of Science ®Google Scholar
• Rosario M, Bridgeman A, Quakkelaar ED, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol.40(7), 1973–1984 (2010).
   PubMed Web of Science ®Google Scholar